IONIS PHARMACEUTICALS INC 8-K

What Happened Ionis Pharmaceuticals announced on June 12, 2026 (presentation at the National Lipid Association Scientific Sessions) new longer‑term MRI‑PDFF data from the open‑label extension of the CORE/CORE2 program (CORE‑OLE) for olezarsen in patients with severe hypertriglyceridemia (sHTG). The presentation reported 12‑month hepatic MRI results from 53 patients who completed one year of 80 mg olezarsen in CORE‑OLE (about 25% of the MRI‑PDFF substudy). Overall, mean hepatic fat fraction (HFF) levels trended back toward baseline by 24 months, while longer‑term treatment continued to show a favorable safety profile.

Key Details

• Data presented June 12, 2026 at the National Lipid Association Scientific Sessions in Chicago.
• 53 patients completed 12 months of CORE‑OLE MRI‑PDFF imaging, representing ~25% of the substudy cohort.
• During CORE‑OLE all patients received 80 mg olezarsen; patients who switched from 50 mg (in the randomized portion) to 80 mg showed less pronounced HFF changes.
• Patient retention was high: >90% of eligible patients who finished CORE/CORE2 enrolled in and remained in CORE‑OLE; safety remained favorable with longer exposure.

Why It Matters These longer‑term imaging data give investors a clearer view of olezarsen’s effect on liver fat over time and its tolerability in sHTG patients. The return of mean HFF toward baseline by 24 months may temper expectations about sustained liver‑fat reduction, while the high retention and continued favorable safety profile support the drug’s tolerability and ongoing clinical development. Investors should view this as an important clinical update on olezarsen’s longer‑term profile rather than a late‑stage regulatory event.